UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

One Ferroptosis-Related Gene-Pair Signature Serves as an Original Prognostic Biomarker in Lung Adenocarcinoma

Frontiers in genetics, 2022-03, Vol.13, p.841712-841712

2022

Volltextzugriff (PDF)

Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study

Targeted oncology, 2021-03, Vol.16 (2), p.165-176

2021

Volltextzugriff (PDF)

Immunoscore Predicts Survival in Early-Stage Lung Adenocarcinoma Patients

Frontiers in oncology, 2020-05, Vol.10, p.691-691

2020

Volltextzugriff (PDF)

Construction of prognostic signature of breast cancer based on N7-Methylguanosine-Related LncRNAs and prediction of immune response

Frontiers in genetics, 2022-10, Vol.13, p.991162-991162

2022

Volltextzugriff (PDF)

Evaluation of Pembrolizumab Monotherapy Efficacy in Advanced Non-Small-Cell Lung Cancer by Serial Monitoring of Circulating Tumor DNA Using Next-Generation Sequencing

Clinical Medicine Insights. Oncology, 2022-02, Vol.16, p.11795549221075326-11795549221075326

2022

Volltextzugriff (PDF)

A novel tumor-targeted delivery system with hydrophobized hyaluronic acid–spermine conjugates (HHSCs) for efficient receptor-mediated siRNA delivery

International journal of pharmaceutics, 2011-07, Vol.414 (1), p.233-243

2011

Volltextzugriff (PDF)

The Effect of Hippocampal Avoidance Whole Brain Radiotherapy on the Preservation of Long-Term Neurocognitive Function in Non-Small Cell Lung Cancer Patients With Brain Metastasis

Technology in cancer research & treatment, 2021, Vol.20, p.15330338211034269-15330338211034269

2021

Volltextzugriff (PDF)

Evaluation safety and efficacy of immune checkpoint blockers (ICB) and radiotherapy combination versus ICB in non‐small cell lung cancer patients with recurrence or metastasis: A systematic review and meta‐analysis

Cancer medicine (Malden, MA), 2023-07, Vol.12 (13), p.13928-13941

2023

Volltextzugriff (PDF)

Differentiation between recurrent gliomas and radiation necrosis using arterial spin labeling perfusion imaging

Experimental and therapeutic medicine, 2016-06, Vol.11 (6), p.2432-2436

2016

Volltextzugriff (PDF)

Detection of apoptotic circulating tumor cells in advanced pancreatic cancer following 5-fluorouracil chemotherapy

Cancer biology & therapy, 2011-10, Vol.12 (8), p.700-706

2011

Volltextzugriff (PDF)

Early Changes of Serum Interleukin 14α Levels Predicts the Response to Anti-PD-1 Therapy in Cancer

Clinical Medicine Insights. Oncology, 2023-01, Vol.17, p.11795549231163369-11795549231163369

2023

Volltextzugriff (PDF)

Adjuvant Osimertinib in Patients With Stage IB to IIIA EGFR Mutation-Positive NSCLC After Complete Tumor Resection: ADAURA China Subgroup Analysis

JTO clinical and research reports, 2024-02, Vol.5 (2), p.100621-100621, Article 100621

2024

Volltextzugriff (PDF)

Successful treatment of an 82‐year‐old COVID‐19 delta variant‐infected patient with haemorrhagic stroke and active prostate cancer brain metastasis

Clinical and translational discovery, 2022-03, Vol.2 (1), p.e20-n/a

2022

Volltextzugriff (PDF)

Raltitrexed versus 5‐fluorouracil with cisplatin and concurrent radiotherapy for locally advanced nasopharyngeal carcinoma: An open labeled, randomized, controlled, and multicenter clinical trial

Cancer medicine (Malden, MA), 2020-09, Vol.9 (17), p.6166-6172

2020

Volltextzugriff (PDF)

Expert consensus on treatment for stage III non‐small cell lung cancer

Medicine advances (Online), 2023-03, Vol.1 (1), p.3-13

2023

Volltextzugriff (PDF)

Tislelizumab Plus Chemotherapy as First-line Treatment for Advanced Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma

Clinical cancer research, 2020-09, Vol.26 (17), p.4542-4550

2020

Volltextzugriff (PDF)

Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer

The New England journal of medicine, 2020-10, Vol.383 (18), p.1711-1723

2020

Volltextzugriff (PDF)

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

The Lancet (British edition), 2019-05, Vol.393 (10183), p.1819-1830

2019

Volltextzugriff (PDF)

Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC

The New England journal of medicine, 2023-07, Vol.389 (2), p.137-147

2023

Volltextzugriff (PDF)

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC

The New England journal of medicine, 2020-01, Vol.382 (1), p.41-50

2020

Volltextzugriff (PDF)

Concurrent durvalumab plus chemoradiation therapy followed by durvalumab in Chinese patients with unresectable stage III non-small cell lung cancer: CRUISER study

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e20576-e20576

2023

Volltextzugriff (PDF)

Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

The New England journal of medicine, 2018-01, Vol.378 (2), p.113-125

2018

Volltextzugriff (PDF)

Hybrid nanopotentiators with dual cascade amplification for glioma combined interventional therapy

Journal of controlled release, 2024-08, Vol.372, p.95-112

2024

Volltextzugriff (PDF)

Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non-Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01)

Journal of clinical oncology, 2023-01, Vol.41 (3), p.651-663

2023

Volltextzugriff (PDF)

1 – 25 von 59

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(54)
Mit Volltextzugriff
(54)

Publikationsform

Artikel
(59)

Sprache

Englisch
(59)

Erscheinungsjahr

n.n

Thema

Science & Technology
(38)
Life Sciences & Biomedicine
(34)
Humans
(24)
Oncology
(22)
Lung Cancer
(13)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(12)
Female
(12)
Lung Neoplasms - Drug Therapy
(12)
Metastasis
(11)
Mutation
(11)
Patients
(11)
Chemotherapy
(10)
Middle Aged
(10)
Cancer Therapies
(9)
Carcinoma, Non-Small-Cell Lung - Genetics
(9)
Lung Neoplasms - Genetics
(9)
Male
(9)
Aged
(8)
Targeted Cancer Therapy
(8)
Non-Small Cell Lung Carcinoma
(7)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

One Ferroptosis-Related Gene-Pair Signature Serves as an Original Prognostic Biomarker in Lung Adenocarcinoma

Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study

Immunoscore Predicts Survival in Early-Stage Lung Adenocarcinoma Patients

Construction of prognostic signature of breast cancer based on N7-Methylguanosine-Related LncRNAs and prediction of immune response

Evaluation of Pembrolizumab Monotherapy Efficacy in Advanced Non-Small-Cell Lung Cancer by Serial Monitoring of Circulating Tumor DNA Using Next-Generation Sequencing

A novel tumor-targeted delivery system with hydrophobized hyaluronic acid–spermine conjugates (HHSCs) for efficient receptor-mediated siRNA delivery

The Effect of Hippocampal Avoidance Whole Brain Radiotherapy on the Preservation of Long-Term Neurocognitive Function in Non-Small Cell Lung Cancer Patients With Brain Metastasis

Evaluation safety and efficacy of immune checkpoint blockers (ICB) and radiotherapy combination versus ICB in non‐small cell lung cancer patients with recurrence or metastasis: A systematic review and meta‐analysis

Differentiation between recurrent gliomas and radiation necrosis using arterial spin labeling perfusion imaging

Detection of apoptotic circulating tumor cells in advanced pancreatic cancer following 5-fluorouracil chemotherapy

Early Changes of Serum Interleukin 14α Levels Predicts the Response to Anti-PD-1 Therapy in Cancer

Adjuvant Osimertinib in Patients With Stage IB to IIIA EGFR Mutation-Positive NSCLC After Complete Tumor Resection: ADAURA China Subgroup Analysis

Successful treatment of an 82‐year‐old COVID‐19 delta variant‐infected patient with haemorrhagic stroke and active prostate cancer brain metastasis

Raltitrexed versus 5‐fluorouracil with cisplatin and concurrent radiotherapy for locally advanced nasopharyngeal carcinoma: An open labeled, randomized, controlled, and multicenter clinical trial

Expert consensus on treatment for stage III non‐small cell lung cancer

Tislelizumab Plus Chemotherapy as First-line Treatment for Advanced Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma

Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC

Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial

Concurrent durvalumab plus chemoradiation therapy followed by durvalumab in Chinese patients with unresectable stage III non-small cell lung cancer: CRUISER study

Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

Hybrid nanopotentiators with dual cascade amplification for glioma combined interventional therapy

Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non-Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01)

Suchergebnisse filtern